Clinical trials: Large B Cell Diffuse Lymphoma, open to volunteers
Diffuse Large B Cell Lymphoma
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
The purpose of this study is to investigate the safety and tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT07368270
- Testing
- Anti-PD1 armored CD19 CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
To evaluate the efficacy and adverse effects of lenalidomide combined with G-CHOP(LO-CHOP) in the treatment of newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL).
- Trial name
- NCT06151080
- Testing
- Lenalidomide combined with G-CHOP (LO CHOP)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Diffuse Large B-Cell Lymphoma
Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
To evaluate the efficacy and safety of the Pro-Pola （Pomalidomide, rituximab, orelabrutinib and polatuzumab vedotin) regimen in elderly patients (aged ≥70 years) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT07072208
- Testing
- Induction therapy-Pro regimen, Consolidation therapy-Pro-pola regimen
- Where
- China
- Volunteers
- 43 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
This trial is a phase I clinical trial aimed at the safety and tolerability of RC19D2 cell injection in the treatment of CD19 positive patients with recurrent or refractory diffuse large B-cell lymphoma
- Trial name
- NCT06047197
- Testing
- RC19D2 cell injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Beijing Yongtai Ruike Biotechnology Company Ltd
Refractory/Recurrent Central Nervous System Lymphoma
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
This study is designed to evaluate the safety and efficacy of cord blood-derived CAR-NK019 in the treatment of refractory/relapsed central nervous system lymphoma.
- Trial name
- NCT06827782
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back.
- Conditions
- Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Secondary Central Nervous System Lymphoma
- Trial name
- NCT05256641
- Testing
- Acalabrutinib
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Classic Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Neurocognitive Assessment in Long-Term Survivors of Lymphoma
This is an observational, multicenter, prospective cohort study including patients treated for lymphoma in Italian real-life. Patients eligible for the enrollment in the study will be consecutively included in Italian FIL…
- Conditions
- Classic Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal B Cell Lymphoma
- Trial name
- FIL_LymDeCo (NCT07652476)
- Testing
- anthracycline containing regimen
- Where
- 7 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
This study aims to compare the efficacy and safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/PD1 (Pola-RCHP-X) versus RCHOP-X…
- Trial name
- NCT06516978
- Testing
- Polatuzumab vedotin, Rituximab, Cyclophosphamide
- Volunteers
- 528 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B-cell Lymphoma
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT06120166
- Testing
- Metabolically Armed CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- He Huang
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
This is a Phase I/II multicentre, open-label trial designed to evaluate the efficacy, safety, tolerability, timing of administration and pharmacokinetics (PK) of a novel chimeric antigen receptor (CAR) T-cell engager, ALETA-001…
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular
- Trial name
- NCT06045910
- Testing
- ALETA-001
- Where
- 7 sites in United Kingdom
- Volunteers
- 84 people
- Sponsor
- Cancer Research UK
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity.
- Trial name
- GOLD (NCT06828991)
- Testing
- Mosunetuzumab, ClonoSEQ
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Danielle Wallace
Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer
The TASTY-steering Study
This is a multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands.
- Conditions
- Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer, Stage II-IV Diffuse Large B Cell Lymphoma
- Trial name
- TASTY-steering (NCT07258563)
- Testing
- Taste steering
- Where
- 11 sites in Netherlands
- Volunteers
- 201 people
- Sponsor
- University Medical Center Groningen
Hematologic Malignancy, Large B-cell Lymphoma
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease.
- Conditions
- Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT05887167
- Testing
- autologous hematopoietic stem cells added to planned CAR T
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Joshua Sasine, MD, PhD
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell…
- Conditions
- Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT05990465
- Testing
- Pirtobrutinib, LV20.19 CAR T cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical College of Wisconsin
Primary Central Nervous System Lymphoma
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
This study aims to observe and explore the efficacy and safety of Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) regimen as first-line therapy for primary central nervous system diffuse large B-cell lymphomas(PCNS DLBCL)
- Trial name
- NCT06832267
- Testing
- Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang Cancer Hospital
Lymphoma, Large B-Cell, Diffuse
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Comparison of MODIFIED progression-free survival (Modified-PFS) in high-dose rituximab (500mg/m²) plus CHOP versus standard-dose rituximab plus CHOP in previously untreated (TN) stage III-IV male DLBCL patients
- Trial name
- NCT06573645
- Testing
- Rituximab
- Volunteers
- 428 people
- Sponsor
- Xia Yi
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded…
- Conditions
- Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
- Trial name
- NCT06672705
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Timothy Voorhees
Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL)
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
The goal of this Phase 2, open-label, multicenter clinical trial is to assess the efficacy and safety of accelerated ramp-up and fixed-dose subcutaneous epcoritamab combined with lenalidomide in adults with relapsed or refractory…
- Conditions
- Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory T-cell/Histiocyte-rich Large B-cell Lymphoma, Refractory Transformed Follicular Lymphoma
- Trial name
- BiFAST (NCT07814001)
- Testing
- Epcoritamab, Lenalidomide
- Where
- 15 sites in France
- Volunteers
- 55 people
- Sponsor
- The Lymphoma Academic Research Organisation
Diffuse Large B-cell Lymphoma (DLBCL)
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- Trial name
- NCT03936153
- Testing
- abexinostat
- Where
- 23 sites in China
- Volunteers
- 170 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
Diffuse Large B Cell Lymphoma
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene…
- Trial name
- NCT05757219
- Testing
- Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute